Patent · US Active

Crystalline forms of rosuvastatin calcium salt

US7932387B2 · kind B2 · utility

2Cited by

4References

9Claims

0Family size

Assignee

BASF SE

Inventors

Fritz Blatter · Reinach, CH
Paul Adriaan Van Der Schaaf · Fribourg, CH
Martin Szelagiewicz · Münchenstein, CH

Key dates

Filing date	Jan 23, 2006
Grant date	Apr 26, 2011
Priority date	—
Expiry date	Apr 10, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.